- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05345964
Phase I Study of GST-HG151 Tablets in Healthy Volunteers
April 19, 2022 updated by: Fujian Cosunter Pharmaceutical Co. Ltd
A Safety, Tolerability, Pharmacokinetics, and Food Impact Phase I Study of GST-HG151 Tablets in Single-dose and Multiple-dose in Healthy Volunteers
To Evaluate the Safety, Tolerability, Pharmacokinetics, and Food Impact of GST-HG151 Tablets in Single-dose and Multiple-dose in Healthy Volunteers
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
This trial includes single-dose studies,multiple-dose studies and food Impact studies, The single-dose study included eight doses groups of 5 mg, 15 mg, 30 mg, 60 mg, 90mg, 120 mg, 150 mg and 180 mg.
Based on the results of a single dose, select 2 to 3 doses to conduct multiple dose studies.
To evaluate the tolerance of GST-HG131 tablets in healthy subjects in single and multiple administrations, pharmacokinetic characteristics, drug metabolism and transformation, and the effect of food on GST-HG151 pharmacokinetics.
Study Type
Interventional
Enrollment (Anticipated)
112
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Yanan Tang, Master
- Phone Number: +86 13585734994
- Email: annie_tyn@163.com
Study Locations
-
-
Fuzhou
-
Fujian, Fuzhou, China, 350025
- Recruiting
- Mengchao Hepatpbiliary Hospital of Fujian Medical University
-
Contact:
- Ling Zheng, Bachelor
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Sign the informed consent before the trial and fully understand the content, process and possible adverse reactions of the trial.
- Subjects (including partners) are willing to take effective pregnancy avoidance measures within 6 months after screening to the last study drug administration.
- Male and female healthy subjects aged 18 to 45 years (including 18 and 45 years old).
- Male subjects weigh no less than 50 kg, and female subjects weigh no less than 45 kg. Body mass index (BMI) = body weight (kg) / height 2 (m2), body mass index is in the range of 19 ~ 24 kg / m2 (including critical value).
- Good physical condition (no significant clinical symptoms, normal physical examination. no clinically significant of laboratory examination, vital signs, 12 lead ECG, chest film and abdominal B-ultrasound results).
Exclusion Criteria:
- Allergic constitution (allergic to a variety of drugs, especially ingredients similar to the test drug, or excipients of the test drug, or food).
- Smokers or those who smoke more than 5 cigarettes per day in the three months before screening, or disagree to avoid using any tobacco products during the study.
- Have a history of alcoholism or drink regularly in the three months before screening, those who drink more than 14 units of alcohol per week (1 unit = 360ml of beer with 5% alcohol content or 45ml of spirits with 40% alcohol content or 150ml of wine with 12% alcohol content). Who cannot stop alcohol intake during the study or have a positive breath test for alcoho.
- Blood donation or massive blood loss (≥300 mL, , except female menstruation) or use blood products or blood transfusion within 3 months before screening.
- Have special requirements for diet and cannot abide by the unified diet.
- Took any prescription drugs, over-the-counter drugs, health products or Chinese herbal medicine within 2 weeks before screening.
- Have taken the study drug or participated in the drug clinical trial within three months before taking the study drug(Except for those who did not enter the group).
- Take any drugs that alter liver enzyme activity CYP3A4, including strong inhibitors and inducers that affect CYP3A4, within 28 days before screening or during the study.
- Female subjects were breastfeeding during the screening period or during the trial or were preparing for pregnancy recently or had a positive serum pregnancy result.
- Have been smoking,drinking,or Ingested tea, any caffeinated or xanthine-rich food or drink,or special diet (including dragon fruit, mango, grapefruit, etc.),or have vigorous exercise, or have other factors affecting drug absorption, distribution, metabolism, excretion, etc.within 48hours before screening.
- Ingested chocolate,any alcohol-containing product within 24 hours before screening.
- Subjects who cannot tolerate the standard meal (high fat and high calorie meal) (this strip is only applicable to subjects participating in the food impact study).
- Have a history of dysphagia or any gastrointestinal disease that affects drug absorption.
- Clinical laboratory examinations are abnormal and clinically significant, or the following diseases (including but not limited to gastrointestinal tract, kidney, liver, nerve, blood, endocrine, tumor, lung, Immune, mental or cardiovascular disease).
- HBsAg, HCV, HIV and TPPA have one or more positive.
- had undergone major surgery within 4 weeks before screening or planned surgery during the trial.
- Have a history of drug abuse, or have used drugs within 3 months before screening, or those who are positive in the screening test of urine drugs and drugs (methamphetamine, tetrahydrocannabinol acid, ketamine, cocaine, benzodiazepine, dimethylbisoxyamphetamine and morphine).
- Have difficulty in blood collection, or have a history of needle fainting or cannot tolerate venipuncture.
- Cannot complete the trial for other reasons, or the investigator believes should not be included.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Single-dose experimental group
5mg,15mg,30mg,60mg,90mg,120mg,150mg and 180mg need to complete a single-dose clinical study.
The first two dose groups had 4 subjects in each group (3 received GST-HG151 and 1 received placebo,randomly assigned), and the rest are 10 ubjects in each group (8 received GST-HG151 and 2 received placebo, randomly assigned)
|
Subjects will take GST-HG151 orally(once daily) on Day 1
Subjects will take GST-HG151 orally (once daily) from Day 1 to Day 7
Group A was administered under the fasting condition of Day1 in the first cycle, and under the postprandial conditions of Day8 ~ Day15 in the second cycle.
The two cycles are cross-administered, and the cleaning period is 7 to 14 days.
Group B was administered under the postprandial conditions of Day1 in the first cycle, and under the sky-abdominal conditions of Day8 ~ Day15 in the second cycle.
The two cycles are cross-administered, and the cleaning period is 7 to 14 days.
|
Placebo Comparator: Single-dose control group
5mg,15mg,30mg,60mg,90mg,120mg,150mg and 180mg need to complete a single-dose clinical study.
The first two dose groups had 4 subjects in each group (3 received GST-HG151 and 1 received placebo,randomly assigned), and the rest are 10 ubjects in each group (8 received GST-HG151 and 2 received placebo, randomly assigned)
|
Subjects will take Placebo orally(once daily) on Day 1
Subjects will take Placebo orally (once daily) from day 1 to day 7
|
Active Comparator: Multi-dose experimental group
According to the results of the SAD, it is planned to carry out multiple-dose studies in 2 to 3 dose groups.
Continuous administration, 12 subjects in each group(10 received GST-HG151 and 2 received placebo, randomly assigned)
|
Subjects will take GST-HG151 orally(once daily) on Day 1
Subjects will take GST-HG151 orally (once daily) from Day 1 to Day 7
Group A was administered under the fasting condition of Day1 in the first cycle, and under the postprandial conditions of Day8 ~ Day15 in the second cycle.
The two cycles are cross-administered, and the cleaning period is 7 to 14 days.
Group B was administered under the postprandial conditions of Day1 in the first cycle, and under the sky-abdominal conditions of Day8 ~ Day15 in the second cycle.
The two cycles are cross-administered, and the cleaning period is 7 to 14 days.
|
Placebo Comparator: Multi-dose control group
According to the results of the SAD, it is planned to carry out multiple-dose studies in 2 to 3 dose groups.
Continuous administration, 12 subjects in each group(10 received GST-HG151 and 2 received placebo, randomly assigned)
|
Subjects will take Placebo orally(once daily) on Day 1
Subjects will take Placebo orally (once daily) from day 1 to day 7
|
Active Comparator: Food Impact Study Group A
According to the results of the SAD, it is planned to select 1 dose group,10 subjects(8 received GST-HG151 and 2 received placebo, randomly assigned),two cycles, crossover
|
Subjects will take GST-HG151 orally(once daily) on Day 1
Subjects will take GST-HG151 orally (once daily) from Day 1 to Day 7
Group A was administered under the fasting condition of Day1 in the first cycle, and under the postprandial conditions of Day8 ~ Day15 in the second cycle.
The two cycles are cross-administered, and the cleaning period is 7 to 14 days.
Group B was administered under the postprandial conditions of Day1 in the first cycle, and under the sky-abdominal conditions of Day8 ~ Day15 in the second cycle.
The two cycles are cross-administered, and the cleaning period is 7 to 14 days.
|
Active Comparator: Food Impact Study Group B
According to the results of the SAD, it is planned to select 1 dose group,8 subjects,two cycles, crossover
|
Subjects will take GST-HG151 orally(once daily) on Day 1
Subjects will take GST-HG151 orally (once daily) from Day 1 to Day 7
Group A was administered under the fasting condition of Day1 in the first cycle, and under the postprandial conditions of Day8 ~ Day15 in the second cycle.
The two cycles are cross-administered, and the cleaning period is 7 to 14 days.
Group B was administered under the postprandial conditions of Day1 in the first cycle, and under the sky-abdominal conditions of Day8 ~ Day15 in the second cycle.
The two cycles are cross-administered, and the cleaning period is 7 to 14 days.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
AEs and SAEs
Time Frame: SAD Cohorts : Up to Day 6. MAD Cohorts : Up to Day 14. Food Effect Cohorts : Up to Day 20.
|
Safety assessments such as AEs and SAEs
|
SAD Cohorts : Up to Day 6. MAD Cohorts : Up to Day 14. Food Effect Cohorts : Up to Day 20.
|
Peak Plasma Concentration (Cmax)
Time Frame: Before and at pre-specified time points up to 72 hours after dosing.
|
Plasma samples were collected at different points for pharmacokinetic analysis
|
Before and at pre-specified time points up to 72 hours after dosing.
|
Area Under Curve (AUC)
Time Frame: Before and at pre-specified time points up to 72 hours after dosing.
|
Plasma samples were collected at different points for pharmacokinetic analysis
|
Before and at pre-specified time points up to 72 hours after dosing.
|
T1/2
Time Frame: Before and at pre-specified time points up to 72 hours after dosing.
|
Plasma samples were collected at different points for pharmacokinetic analysis
|
Before and at pre-specified time points up to 72 hours after dosing.
|
Cl/F
Time Frame: Before and at pre-specified time points up to 72 hours after dosing.
|
Plasma samples were collected at different points for pharmacokinetic analysis
|
Before and at pre-specified time points up to 72 hours after dosing.
|
Ae
Time Frame: Before and at pre-specified time points up to 72 hours after dosing.
|
Plasma samples were collected at different points for pharmacokinetic analysis
|
Before and at pre-specified time points up to 72 hours after dosing.
|
Fe
Time Frame: Before and at pre-specified time points up to 72 hours after dosing.
|
Plasma samples were collected at different points for pharmacokinetic analysis
|
Before and at pre-specified time points up to 72 hours after dosing.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Ling Zheng, Bachelor, Mengchao Hepatpbiliary Hospital of Fujian Medical University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 7, 2022
Primary Completion (Anticipated)
March 31, 2023
Study Completion (Anticipated)
May 31, 2023
Study Registration Dates
First Submitted
April 6, 2022
First Submitted That Met QC Criteria
April 19, 2022
First Posted (Actual)
April 26, 2022
Study Record Updates
Last Update Posted (Actual)
April 26, 2022
Last Update Submitted That Met QC Criteria
April 19, 2022
Last Verified
April 1, 2022
More Information
Terms related to this study
Other Study ID Numbers
- GST-HG151-I-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Volunteers
-
AstraZenecaCompletedHealthy Elderly Volunteers | Healthy Young VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
University Hospital, Clermont-FerrandUnite de Nutrition Humaine UMR 1019- INRAE; Unite MetaGenoPolis INRAE; France...CompletedHealthy Volunteers | Frail VolunteersFrance
-
Galera Therapeutics, Inc.CelerionCompletedHealthy | Healthy VolunteersUnited States
-
Newcastle UniversityCompletedGI Glycaemic Index Healthy Volunteers | GL Glycaemic Load Healthy VolunteersUnited Kingdom
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
PMV Pharmaceuticals, IncRecruitingHealthy VolunteersUnited States
Clinical Trials on GST-HG151
-
Fujian Akeylink Biotechnology Co., Ltd.Completed
-
Fujian Akeylink Biotechnology Co., Ltd.Recruiting
-
Fujian Cosunter Pharmaceutical Co. LtdCompleted
-
Fujian Akeylink Biotechnology Co., Ltd.RecruitingChronic Hepatitis bChina
-
Fujian Cosunter Pharmaceutical Co. LtdUnknown
-
Fujian Akeylink Biotechnology Co., Ltd.The First Hospital of Jilin UniversityRecruitingPharmacokinetics | Food Affect | Single Ascending Dose | Maximum Applicable DoseChina
-
Fujian Cosunter Pharmaceutical Co. LtdUnknown
-
Baylor College of MedicineGeorge Washington University; Children's National Research InstituteCompletedHookworm Infection | Hookworm DiseaseUnited States
-
Fujian Cosunter Pharmaceutical Co. LtdUnknownSolid Tumor | C-Met Mutation-Related TumorsChina
-
Fujian Akeylink Biotechnology Co., Ltd.CompletedPharmacokinetics and Safety of GST-HG171 Tablets in Subjects With Impaired and Normal Liver FunctionCOVID-19 PneumoniaChina